Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line

Neoplasia

Volumn 7, Issue 6, 2005, Pages 594-602

  Zhang, Lidong ^a   Zhu, Hongbo ^a   Teraishi, Fuminori ^a   Davis, John J ^a,b   Guo, Wei ^a   Fan, Zhen ^a   Fang, Bingliang ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Apoptosis; Caspase 8; Degradation; Resistance; TRAIL

Indexed keywords

CASPASE 8; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; COLON CANCER; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MISSENSE MUTATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 22044441646     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04688     Document Type: Article

References (35)

1. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, and Ashkenazi A (1996). Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271, 12687-12690.
2. Ashkenazi A and Dixit VM (1999). Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11, 255-260.
3. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al. (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5, 157-163.
4. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, and Smyth MJ (2002). Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168, 1356-1361.
5. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, and Okumura K (2001). Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7, 94-100.
6. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, and Debatin KM (2001). Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogens 20, 5865-5877.
7. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N, and Brodeur GM (2001). Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 61, 1314-1319.
8. Zhang L, Gu J, Lin T, Huang X, Roth JA, and Fang B (2002). Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Gene Ther 9, 1262-1270.
9. Jin Z, McDonald ER, III, Dicker DT, and El Deiry WS (2004). Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 279, 35829-35839.
10. Kim K, Fisher MJ, Xu SQ, and El Deiry WS (2000). Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6, 335-346.
11. Shin MS, Kim HS, Lee SH, Park WS, Kim SY, Park JY, Lee JH, Lee SK, Lee SN, Jung SS, et al. (2001). Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 61, 4942-4946.
12. Kuang AA, Diehl GE, Zhang J, and Winoto A (2000). FADD is required for DR4- and DR5-mediated apoptosis: lack of TRAIL-induced apoptosis in FADD-deficient mouse embryonic fibroblasts, J Biol Chem 275, 25065-25068.
13. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, et al. (1997). Inhibition of death receptor signals by cellular FLIP. Nature 388, 190-195.
14. Fulda S, Meyer E, and Debatin KM (2002). Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogens 21, 2283-2294.
15. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, and Ashkenazi A (2002). Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8, 274-281.
16. Wang GQ, Gastman BR, Wieckowski E, Goldstein LA, Gambotto A, Kim TH, Fang B, Rabinovitz A, Yin XM, and Rabinowich H (2001). A role for mitochondrial Bak in apoptotic response to anticancer drugs. J Biol Chem 276, 34307-34317.
17. Ng CP, Zisman A, and Bonavida B (2002). Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate 53, 286-299.
18. Zhang XD, Zhang XY, Gray CP, Nguyen T, and Hersey P (2001). Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res 61, 7339-7348.
19. Zhang L, Zhu H, Davis JJ, Jacob D, Wu S, Teraishi F, Gutierrez A, Wang Y, and Fang B (2004). Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death. Cancer Biol Ther 3, 296-301.
20. Liu B, Peng D, Lu Y, Jin W, and Fan Z (2002). A novel single amino acid deletion caspase-8 mutant in cancer cells that lost proapoptotic activity. J Biol Chem 277, 30159-30164.
21. McDonald ER, III and El Deiry WS (2004). Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc Natl Acad Sci USA 101, 6170-6175.
22. Ozoren N and El Deiry WS (2002). Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 4, 551-557.
23. Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, Gazdar A, Blenis J, Arnott D, and Ashkenazi A (2001). Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276, 46639-46646.
24. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, and Tschopp J (2000). TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2, 241-243.
25. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, and Walczak H (2002). Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J 21, 4520-4530.
26. Scaffidi C, Schmitz I, Krammer PH, and Peter ME (1999). The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 274, 1541-1548.
27. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, and Kidd VJ (2000). Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6, 529-535.
28. Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C, Zangemeister-Wittke U, and Stahel R (2003). Silencing of death receptor and caspase-8 expression In small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 10, 356-364.
29. Iolascon A, Borriello A, Giordani L, Cucciolla V, Moretti A, Monno F, Criniti V, Marzullo A, Criscuolo M, and Ragione FD (2003). Caspase 3 and 8 deficiency In human neuroblastoma. Cancer Genet Cytogenet 146, 41-47.
30. Zuzak TJ, Steinhoff DF, Sutton LN, Phillips PC, Eggert A, and Grotzer MA (2002). Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. Eur J Cancer 38, 83-91.
31. Toyozumi Y, Arima N, Izumaru S, Kalo S, Morimatsu M, and Nakashima T (2004). Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells. Int J Oncol 25, 721-728.
32. Lee JC and Peter ME (2003). Regulation of apoptosis by ubiquitination. Immunol Rev 193, 39-47.
33. Zhang HG, Wang J, Yang X, Hsu HC, and Mountz JD (2004). Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23, 2009-2015.
34. Zhu H, Zhang L, Huang X, Davis JJ, Jacob DA, Teraishi F, Chiao P, and Fang B (2004). Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther 9, 666-673.
35. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, and Hung MC (2004). Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6, 931-940.